Caladrius Biosciences Inc. (CLBS) Shares Gap Up to $0.52
Caladrius Biosciences Inc. (NASDAQ:CLBS) shares gapped up before the market opened on Thursday . The stock had previously closed at ($3.30), but opened at $0.52. Caladrius Biosciences shares last traded at $5.48, with a volume of 146,185 shares traded.
A number of research firms have weighed in on CLBS. Zacks Investment Research lowered shares of Caladrius Biosciences from a “buy” rating to a “hold” rating in a research report on Friday. Maxim Group restated a “hold” rating on shares of Caladrius Biosciences in a report on Saturday, May 14th. Rodman & Renshaw upgraded shares of Caladrius Biosciences to a “buy” rating in a report on Saturday, April 30th. Finally, HC Wainwright upgraded shares of Caladrius Biosciences from a “neutral” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Friday, April 29th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Caladrius Biosciences has a consensus rating of “Buy” and an average price target of $2.83.
The firm’s 50 day moving average price is $5.46 and its 200-day moving average price is $6.16. The firm’s market cap is $32.70 million.
In related news, Director Eric Wei sold 87,500 shares of the firm’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $0.60, for a total value of $52,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Caladrius Biosciences, Inc, formerly NeoStem, Inc, is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (CSCs).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.